MapLight Therapeutics details 2026 shareholder vote results

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

8-K Event Classification

Key Figures

Key Terms

What did MapLight Therapeutics (MPLT) report from its 2026 annual meeting?

How many MapLight Therapeutics (MPLT) shares were represented at the 2026 annual meeting?

Who was elected to the MapLight Therapeutics (MPLT) board at the 2026 meeting?

What were the vote totals for MapLight Therapeutics (MPLT) director elections?

Did MapLight Therapeutics (MPLT) shareholders ratify the auditor for 2026?

What percentage of MapLight Therapeutics (MPLT) shareholders participated in the 2026 meeting?

MapLight Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders.

(Moderate)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

MapLight Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders. Of the 42,610,079 shares outstanding as of the record date, 36,883,750 shares, or approximately 86.56%, were present or represented by proxy, indicating strong participation.

Stockholders elected three directors to serve until the 2029 annual meeting. Martin Babler received 31,424,194 votes for and 3,575,737 withheld, Troy Cox received 34,979,012 votes for and 20,919 withheld, and George Pavlov received 34,220,342 votes for and 779,589 withheld, with 1,883,819 broker non-votes.

Stockholders also ratified the selection of RSM US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 36,859,217 votes for, 22,332 against, and 2,201 abstentions.

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Shares outstanding: 42,610,079 shares Shares represented at meeting: 36,883,750 shares Votes for Babler: 31,424,194 votes +3 more

6 metrics

Shares outstanding 42,610,079 shares Outstanding as of the record date for the 2026 annual meeting

Shares represented at meeting 36,883,750 shares Approximately 86.56% participation at 2026 annual meeting

Votes for Babler 31,424,194 votes Director election of Martin Babler

Votes for Cox 34,979,012 votes Director election of Troy Cox

Votes for Pavlov 34,220,342 votes Director election of George Pavlov

Votes for auditor ratification 36,859,217 votes Ratification of RSM US LLP for fiscal year ending December 31, 2026

broker non-votes, independent registered public accounting firm, emerging growth company, annual meeting of stockholders

4 terms

broker non-votes financial

"Broker Non-Votes: 1,883,819"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm financial

"Ratification of the selection of RSM US LLP as independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

annual meeting of stockholders financial

"held its 2026 annual meeting of stockholders (the “Annual Meeting”)"

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

MapLight Therapeutics reported voting results from its 2026 annual meeting of stockholders. Shareholders elected three directors for terms expiring at the 2029 annual meeting and ratified RSM US LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

At the 2026 annual meeting, 36,883,750 MapLight Therapeutics shares were present or represented by proxy. This represented approximately 86.56% of the 42,610,079 shares outstanding as of the record date, indicating a high level of shareholder participation in the voting process.

Shareholders elected Martin Babler, Troy Cox, and George Pavlov to the MapLight Therapeutics board. Each will serve as a director until the 2029 annual meeting of stockholders and until a successor is elected and qualified, based on majority support in the shareholder vote.

For director elections, Martin Babler received 31,424,194 votes for and 3,575,737 withheld. Troy Cox received 34,979,012 for and 20,919 withheld, while George Pavlov received 34,220,342 for and 779,589 withheld. There were 1,883,819 broker non-votes for this proposal.

Yes, shareholders ratified RSM US LLP as MapLight Therapeutics’ independent registered public accounting firm for 2026. The ratification received 36,859,217 votes for, 22,332 votes against, and 2,201 abstentions, with no broker non-votes reported on this proposal.

Approximately 86.56% of MapLight Therapeutics shares outstanding as of the record date were present or represented by proxy. Specifically, 36,883,750 shares participated out of 42,610,079 outstanding shares, reflecting strong shareholder engagement at the 2026 annual meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/24/2026 - 07:12 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2026

MapLight Therapeutics, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-42914	83-2163243
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

800 Chesapeake Drive

Redwood City, California 94063

(Address of principal executive offices)

Registrant’s telephone number, including area code: (617) 984-6300

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading symbol(s)	Name of each exchange on which registered
Voting Common Stock, $0.0001 par value per share	MPLT	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07

Submission of Matters to a Vote of Security Holders.

On June 23, 2026, MapLight Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2026 (the “Proxy Statement”). Of the 42,610,079 shares outstanding as of the record date, 36,883,750 shares, or approximately 86.56%, were present or represented by proxy at the Annual Meeting. Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

Proposal No. 1: Election of three nominees to serve as directors until the 2029 annual meeting of stockholders and until their respective successors are elected and qualified. The votes were cast as follows:


Name	Votes For		Votes Withheld
Martin Babler		31,424,194		3,575,737
Troy Cox		34,979,012		20,919
George Pavlov		34,220,342		779,589

Broker Non-Votes: 1,883,819

All nominees were elected.

Proposal No. 2: Ratification of the selection of RSM US LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes were cast as follows:


	Votes For		Votes Against		Abstained
Ratification of selection of RSM US LLP		36,859,217		22,332		2,201

Broker Non-Votes: 0

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

MapLight Therapeutics, Inc.

Dated: June 24, 2026

/s/ Christopher A. Kroeger

Christopher A. Kroeger, M.D.

Chief Executive Officer

3 documents